The present application relates to a novel AMPelopsin unsaturated sodium salt compound (AMP-Na), a method for preparing the same and the applications thereof. The physicochemical properties of AMP-Na according to the present application are significantly altered compared to those of AMPelopsin (AMP). AMP-Na shows significantly reduced toxicity than AMP as evidenced by the in vivo acute toxicity studies. As demonstrated by pharmacological evaluation, AMP-Na exhibits synergistic action when administered in combination with clinically used anti-cancer drugs, therefore reducing their dosages without compromising their therapeutic effects.
